Mannkind Corp (MNKD)

$3.78 +0.14 (3.85%)
Market Cap 1.10B
Revenue (ttm) 348.97M
Net Income (ttm) 5.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 1.68%
Debt to Equity Ratio -7.13
Volume 16,496,023
Avg Vol 5,736,268
Day's Range N/A - N/A
Shares Out 308.95M
Stochastic %K 95%
Beta 1.04
Analysts Strong Sell
Price Target $7.47

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provi...

Industry: Biotechnology
Sector: Healthcare
Phone: 818 661 5000
Address:
1 Casper Street, Danbury, United States
OpenOutcrier
OpenOutcrier May. 29 at 8:00 PM
RECAP 5/29 Chatter: $MNKD + Inhaled Insulin Approval $ $ELV + CMS Reprieve $OCS - Diabetic Macular Edema Fail $DVN + Marcellus Offer Live Breaking trading news www.openoutcrier.com
0 · Reply
bigskyliving
bigskyliving May. 29 at 7:58 PM
$MNKD Picked up some more at $3.69. This stock is so predictable as far as how it trades. Always the best time to buy is 30 minutes to the close. They flush it every time, and with a couple of minutes left, they bring it back a bit.
0 · Reply
investing58585
investing58585 May. 29 at 7:55 PM
$MNKD but buy , thia will break 4 now
1 · Reply
therightpicks
therightpicks May. 29 at 7:55 PM
$MNKD they waited all this time for approval. they get approval and we fizzle out
0 · Reply
BuyinOnTime
BuyinOnTime May. 29 at 7:55 PM
$MNKD no way theres an offering. Looking forward to a good management plan on the call in 35minutes!
0 · Reply
digitalspurs1
digitalspurs1 May. 29 at 7:54 PM
$MNKD wow might see new HOD before close at this rate. Shake out the weak hands!!
0 · Reply
justme_DC
justme_DC May. 29 at 7:53 PM
$MNKD Hate to admit, but even if the approval was indeed mostly priced in....this looks like an offering shortly to follow.
0 · Reply
ZeroDog
ZeroDog May. 29 at 7:53 PM
$MNKD as usual this stock is a clown show to not react positively to FDA approval
1 · Reply
investing58585
investing58585 May. 29 at 7:52 PM
$MNKD shaking weak hands before run🚀🚀👀
0 · Reply
houtrader
houtrader May. 29 at 7:51 PM
$MNKD again for the biotech gamblers This is NOT 1 drug biotech. This is a somewhat diversified specialty pharma with multiple approved products. The biotech games you are used to have not applied here for years.
1 · Reply
Latest News on MNKD
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

May 29, 2026, 2:00 PM EDT - 2 hours ago

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

US FDA approves MannKind's inhaled insulin for children

May 29, 2026, 12:44 PM EDT - 3 hours ago

US FDA approves MannKind's inhaled insulin for children

MannKind announces FDA approval of Afrezza for use in children aged 6 and older

2026-05-29T16:35:11.000Z - 3 hours ago

MannKind announces FDA approval of Afrezza for use in children aged 6 and older

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

May 29, 2026, 12:30 PM EDT - 3 hours ago

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MannKind to Present at Jefferies Global Healthcare Conference

May 27, 2026, 4:00 PM EDT - 2 days ago

MannKind to Present at Jefferies Global Healthcare Conference

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

May 27, 2026, 9:05 AM EDT - 2 days ago

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

MannKind Transcript: AGM 2026

May 20, 2026, 9:00 AM EDT - 9 days ago

MannKind Transcript: AGM 2026

MannKind price target lowered to $7 from $8 at Mizuho

2026-05-07T15:49:43.000Z - 22 days ago

MannKind price target lowered to $7 from $8 at Mizuho

MannKind price target raised to $10 from $8 at H.C. Wainwright

2026-05-07T11:37:11.000Z - 22 days ago

MannKind price target raised to $10 from $8 at H.C. Wainwright

MannKind price target raised to $10 from $8 at Wells Fargo

2026-05-07T10:51:50.000Z - 22 days ago

MannKind price target raised to $10 from $8 at Wells Fargo

MannKind reports Q1 EPS (2c), consensus 1c

2026-05-07T01:17:30.000Z - 22 days ago

MannKind reports Q1 EPS (2c), consensus 1c

MannKind Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 22 days ago

MannKind Earnings Call Transcript: Q1 2026

MannKind Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 22 days ago

MannKind Earnings release: Q1 2026

MannKind Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 22 days ago

MannKind Quarterly report: Q1 2026

MannKind Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 22 days ago

MannKind Slides: Q1 2026

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 4:01 PM EDT - 23 days ago

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

May 6, 2026, 6:30 AM EDT - 23 days ago

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

Apr 29, 2026, 4:01 PM EDT - 4 weeks ago

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

MannKind price target lowered to $8 from $10 at Mizuho

2026-04-13T14:45:40.000Z - 6 weeks ago

MannKind price target lowered to $8 from $10 at Mizuho

MannKind price target lowered to $6 from $7 at Truist

2026-04-08T12:35:39.000Z - 7 weeks ago

MannKind price target lowered to $6 from $7 at Truist

Theravance Biopharma price target raised to $17 from $14 at B. Riley

2026-04-07T12:31:26.000Z - 7 weeks ago

Theravance Biopharma price target raised to $17 from $14 at B. Riley

TBPH

MannKind Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 7 weeks ago

MannKind Proxy statement: Proxy filing

MannKind Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 7 weeks ago

MannKind Proxy statement: Proxy filing

MannKind Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 1:00 PM EDT - 2 months ago

MannKind Transcript: Barclays 28th Annual Global Healthcare Conference

MannKind Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 3:40 PM EDT - 2 months ago

MannKind Transcript: Leerink Global Healthcare Conference 2026

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Mar 9, 2026, 9:05 AM EDT - 2 months ago

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

MannKind Announces Settlement of Convertible Senior Notes

Mar 5, 2026, 4:30 PM EST - 3 months ago

MannKind Announces Settlement of Convertible Senior Notes

MannKind price target lowered to $8 from $10 at Wedbush

2026-03-05T14:03:29.000Z - 3 months ago

MannKind price target lowered to $8 from $10 at Wedbush

UTHR

MannKind to Participate in Upcoming Investor Conferences

Mar 4, 2026, 9:00 AM EST - 3 months ago

MannKind to Participate in Upcoming Investor Conferences

Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink

2026-02-27T18:27:37.000Z - 3 months ago

Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink

IBB SLNO XBI XLV

MannKind price target lowered to $7 from $8 at Wells Fargo

2026-02-27T12:57:54.000Z - 3 months ago

MannKind price target lowered to $7 from $8 at Wells Fargo

MannKind price target lowered to $8 from $11 at H.C. Wainwright

2026-02-27T12:11:17.000Z - 3 months ago

MannKind price target lowered to $8 from $11 at H.C. Wainwright

MannKind downgraded to Sector Perform from Outperform at RBC Capital

2026-02-27T10:30:32.000Z - 3 months ago

MannKind downgraded to Sector Perform from Outperform at RBC Capital

UTHR

MannKind Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 11:20 AM EST - 3 months ago

MannKind Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

MannKind Earnings Call Transcript: Q4 2025

Feb 26, 2026, 9:00 AM EST - 3 months ago

MannKind Earnings Call Transcript: Q4 2025

MannKind Annual report: Q4 2025

Feb 26, 2026, 9:00 AM EST - 3 months ago

MannKind Annual report: Q4 2025

MannKind Earnings release: Q4 2025

Feb 26, 2026, 9:00 AM EST - 3 months ago

MannKind Earnings release: Q4 2025

MannKind Slides: Q4 2025

Feb 26, 2026, 9:00 AM EST - 3 months ago

MannKind Slides: Q4 2025

MannKind reports Q4 EPS (5c) vs 3c last year

2026-02-26T13:23:42.000Z - 3 months ago

MannKind reports Q4 EPS (5c) vs 3c last year

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 8:00 AM EST - 3 months ago

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind

2026-02-25T19:35:40.000Z - 3 months ago

RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind

UTHR

Leerink sees MannKind selloff as ‘overreaction’ to headline news

2026-02-25T18:20:50.000Z - 3 months ago

Leerink sees MannKind selloff as ‘overreaction’ to headline news

UTHR

H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition

2026-02-25T16:55:34.000Z - 3 months ago

H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition

UTHR

MannKind sinks after United Therapeutics announces soft-mist inhaler

2026-02-25T16:10:16.000Z - 3 months ago

MannKind sinks after United Therapeutics announces soft-mist inhaler

UTHR

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 9:00 AM EST - 3 months ago

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 18, 2026, 9:00 AM EST - 3 months ago

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

MannKind says first patient enrolled in INHALE-1ST study of Afrezza

2026-02-09T11:11:25.000Z - 3 months ago

MannKind says first patient enrolled in INHALE-1ST study of Afrezza

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

Feb 9, 2026, 6:05 AM EST - 3 months ago

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

Jan 26, 2026, 6:05 AM EST - 4 months ago

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

Jan 12, 2026, 3:57 PM EST - 4 months ago

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

AAPL DT GLD ITRN NVDA OMC UTHR

MannKind Slides: Corporate presentation

Jan 10, 2026, 7:00 AM EST - 4 months ago

MannKind Slides: Corporate presentation

MannKind Provides Business Updates and 2026 Growth Drivers

Jan 8, 2026, 8:05 AM EST - 5 months ago

MannKind Provides Business Updates and 2026 Growth Drivers

MannKind Shares FUROSCIX® Business Updates

Dec 23, 2025, 8:05 AM EST - 5 months ago

MannKind Shares FUROSCIX® Business Updates

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

Dec 1, 2025, 8:05 AM EST - 6 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

MannKind Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 6:30 AM EST - 6 months ago

MannKind Transcript: Jefferies London Healthcare Conference 2025

MannKind to Present at the Jefferies Global Healthcare Conference

Nov 11, 2025, 4:05 PM EST - 7 months ago

MannKind to Present at the Jefferies Global Healthcare Conference

MannKind Transcript: Study Update

Nov 10, 2025, 9:00 AM EST - 7 months ago

MannKind Transcript: Study Update

MannKind Press release: Study Update

Nov 10, 2025, 9:00 AM EST - 7 months ago

MannKind Press release: Study Update

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

Nov 10, 2025, 8:00 AM EST - 7 months ago

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

Nov 6, 2025, 9:00 AM EST - 7 months ago

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

MannKind Earnings Call Transcript: Q3 2025

Nov 5, 2025, 9:00 AM EST - 7 months ago

MannKind Earnings Call Transcript: Q3 2025

MannKind Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 7 months ago

MannKind Quarterly report: Q3 2025

MannKind Earnings release: Q3 2025

Nov 5, 2025, 9:00 AM EST - 7 months ago

MannKind Earnings release: Q3 2025

MannKind Slides: Q3 2025

Nov 5, 2025, 9:00 AM EST - 7 months ago

MannKind Slides: Q3 2025

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:00 AM EST - 7 months ago

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

Oct 29, 2025, 4:05 PM EDT - 7 months ago

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

Oct 13, 2025, 8:05 AM EDT - 8 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Oct 7, 2025, 9:02 AM EDT - 8 months ago

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

Sep 29, 2025, 6:05 AM EDT - 8 months ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

Sep 16, 2025, 12:17 PM EDT - 9 months ago

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SCPH

MannKind Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 2:35 PM EDT - 9 months ago

MannKind Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

MannKind Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 11:30 AM EDT - 9 months ago

MannKind Transcript: H.C. Wainwright 27th Annual Global Investment Conference

MannKind Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:45 AM EDT - 9 months ago

MannKind Transcript: Cantor Global Healthcare Conference 2025

MannKind Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 4:30 PM EDT - 9 months ago

MannKind Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 4:05 PM EDT - 9 months ago

MannKind to Present at Upcoming Investor Conferences

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Aug 27, 2025, 8:05 AM EDT - 9 months ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

MannKind Transcript: M&A Announcement

Aug 25, 2025, 8:30 AM EDT - 9 months ago

MannKind Transcript: M&A Announcement

MannKind Press release: M&A Announcement

Aug 25, 2025, 8:30 AM EDT - 9 months ago

MannKind Press release: M&A Announcement

MannKind Earnings Call Transcript: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 10 months ago

MannKind Earnings Call Transcript: Q2 2025

MannKind Quarterly report: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 10 months ago

MannKind Quarterly report: Q2 2025

MannKind Earnings release: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 10 months ago

MannKind Earnings release: Q2 2025

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:10 AM EDT - 10 months ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Aug 6, 2025, 7:05 AM EDT - 10 months ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

MannKind Slides: Corporate Presentation

Aug 6, 2025, 7:00 AM EDT - 10 months ago

MannKind Slides: Corporate Presentation

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jul 30, 2025, 4:05 PM EDT - 10 months ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

Jun 9, 2025, 4:05 PM EDT - 1 year ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

MannKind Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 2:35 PM EDT - 1 year ago

MannKind Transcript: Jefferies Global Healthcare Conference 2025

MannKind Slides: FY 2025

Jun 5, 2025, 2:35 PM EDT - 1 year ago

MannKind Slides: FY 2025

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025, 9:15 AM EDT - 1 year ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

MannKind Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 8:00 AM EDT - 1 year ago

MannKind Transcript: RBC Capital Markets Global Healthcare Conference 2025

MannKind Earnings Call Transcript: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings Call Transcript: Q1 2025

MannKind Quarterly report: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

MannKind Quarterly report: Q1 2025

MannKind Earnings release: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings release: Q1 2025

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 1 year ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

May 1, 2025, 4:05 PM EDT - 1 year ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Apr 7, 2025, 12:30 PM EDT - 1 year ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

MannKind Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

MannKind Proxy statement: Proxy Filing

MannKind Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

MannKind Proxy statement: Proxy Filing

MannKind Transcript: Barclays 26th Annual Global Healthcare Conference

Mar 12, 2025, 1:30 PM EDT - 1 year ago

MannKind Transcript: Barclays 26th Annual Global Healthcare Conference

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Mar 10, 2025, 6:05 AM EDT - 1 year ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

MannKind Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Earnings Call Transcript: Q4 2024

MannKind Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Annual report: Q4 2024

MannKind Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Earnings release: Q4 2024

MannKind Slides: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Slides: Q4 2024

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 26, 2025, 4:05 PM EST - 1 year ago

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Feb 19, 2025, 4:05 PM EST - 1 year ago

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

MannKind Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 11:20 AM EST - 1 year ago

MannKind Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

MannKind Expands Executive Leadership Team

Jan 6, 2025, 4:30 PM EST - 1 year ago

MannKind Expands Executive Leadership Team

MannKind Transcript: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

MannKind Transcript: Study Result

MannKind Press release: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

MannKind Press release: Study Result

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Dec 16, 2024, 6:05 AM EST - 1 year ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

Dec 11, 2024, 6:00 AM EST - 1 year ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

MannKind Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 1:15 PM EST - 1 year ago

MannKind Transcript: UBS Global Healthcare Conference 2024

MannKind Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

MannKind Earnings Call Transcript: Q3 2024

MannKind Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

MannKind Quarterly report: Q3 2024

MannKind Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

MannKind Earnings release: Q3 2024

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Nov 7, 2024, 4:02 PM EST - 1 year ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

MannKind to Present at 2024 UBS Healthcare Conference

Nov 5, 2024, 4:15 PM EST - 1 year ago

MannKind to Present at 2024 UBS Healthcare Conference

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

Nov 4, 2024, 6:05 AM EST - 1 year ago

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

Oct 31, 2024, 4:05 PM EDT - 1 year ago

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Oct 30, 2024, 9:00 PM EDT - 1 year ago

First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

OpenOutcrier
OpenOutcrier May. 29 at 8:00 PM
RECAP 5/29 Chatter: $MNKD + Inhaled Insulin Approval $ $ELV + CMS Reprieve $OCS - Diabetic Macular Edema Fail $DVN + Marcellus Offer Live Breaking trading news www.openoutcrier.com
0 · Reply
bigskyliving
bigskyliving May. 29 at 7:58 PM
$MNKD Picked up some more at $3.69. This stock is so predictable as far as how it trades. Always the best time to buy is 30 minutes to the close. They flush it every time, and with a couple of minutes left, they bring it back a bit.
0 · Reply
investing58585
investing58585 May. 29 at 7:55 PM
$MNKD but buy , thia will break 4 now
1 · Reply
therightpicks
therightpicks May. 29 at 7:55 PM
$MNKD they waited all this time for approval. they get approval and we fizzle out
0 · Reply
BuyinOnTime
BuyinOnTime May. 29 at 7:55 PM
$MNKD no way theres an offering. Looking forward to a good management plan on the call in 35minutes!
0 · Reply
digitalspurs1
digitalspurs1 May. 29 at 7:54 PM
$MNKD wow might see new HOD before close at this rate. Shake out the weak hands!!
0 · Reply
justme_DC
justme_DC May. 29 at 7:53 PM
$MNKD Hate to admit, but even if the approval was indeed mostly priced in....this looks like an offering shortly to follow.
0 · Reply
ZeroDog
ZeroDog May. 29 at 7:53 PM
$MNKD as usual this stock is a clown show to not react positively to FDA approval
1 · Reply
investing58585
investing58585 May. 29 at 7:52 PM
$MNKD shaking weak hands before run🚀🚀👀
0 · Reply
houtrader
houtrader May. 29 at 7:51 PM
$MNKD again for the biotech gamblers This is NOT 1 drug biotech. This is a somewhat diversified specialty pharma with multiple approved products. The biotech games you are used to have not applied here for years.
1 · Reply
Keeportrade
Keeportrade May. 29 at 7:51 PM
$MNKD It was just filled.
0 · Reply
kule04
kule04 May. 29 at 7:50 PM
$MNKD bro how is this even possible
1 · Reply
kapy1544
kapy1544 May. 29 at 7:50 PM
$MNKD this would be so Mnkd like if actually ends the day negative on fda approval. Honestly it’s impressive
0 · Reply
Harryx1
Harryx1 May. 29 at 7:49 PM
$MNKD It's the MNKD way 15M shares to go up 30 cents and 500,000 share to go down 30+ cents. AMAZING.
1 · Reply
Monkey7779192
Monkey7779192 May. 29 at 7:49 PM
$MNKD Below 3.50 on Monday as they do offering aswell.
0 · Reply
jdfav
jdfav May. 29 at 7:48 PM
$MNKD Did the market halt!
0 · Reply
GroundskeeperWilly
GroundskeeperWilly May. 29 at 7:48 PM
$MNKD so i’m guessing no 7 today, pretty underwhelming. hoping for a good call AH.
0 · Reply
ghcolleen88
ghcolleen88 May. 29 at 7:48 PM
$MNKD It’s just amazing that these crooks keep manipulating us. Investigation really needed
1 · Reply
Moneyman2019
Moneyman2019 May. 29 at 7:45 PM
$MNKD Why no pop on this news? Am I missing something?
2 · Reply
StocktwitsNews
StocktwitsNews May. 29 at 7:43 PM
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children $MNKD https://stocktwits.com/news/equity/markets/mnkd-stock-jumps-on-receiving-fda-approval-for-afrezza-to-treat-diabetes-in-children/cZgSyurReMx
0 · Reply
Outcomes
Outcomes May. 29 at 7:42 PM
$MNKD https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-fda-approval-afrezzar-first-and-only-inhaled
0 · Reply
KingsXruleS
KingsXruleS May. 29 at 7:41 PM
$MNKD No excuses now. Execute. EPS. Let’s go! If you need the Glengarry pep talk I can send it.
0 · Reply